Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Biomolecules · 15.07.2025 · 15 (7) · 1017
DOI: 10.3390/biom15071017 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Biomolecules, online erschienen am 15.07.2025. Verfasst von Laura Chulenbayeva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiome, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan. Hauptthemen laut MEDLINE: Fatty Acids, Volatile, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan, Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.
Abstract (Originalsprache)
Background
Reduced short-chain fatty acids (SCFAs) in inflammatory bowel disease (IBD) impair the gut barrier and immune function, promoting inflammation and highlighting microbiome-targeted therapies’ therapeutic potential. The purpose of this meta-analysis was to study the changes in SCFAs in IBD and their potential role in the occurrence and development of IBD.
Methods
The analysis employed a random-effects model to assess the standardized mean difference (SMD) with a 95% confidence interval. A literature search was conducted in databases from 2014 to 20 July 2024 to identify studies investigating SCFAs in IBD.
Results
Subgroup analyses revealed a significant reduction in fecal SCFA levels—specifically butyrate, acetate, and propionate—in all IBD subgroups compared to healthy controls. Active IBD showed a greater decrease in butyrate (p = 0.004), and UC showed a notable reduction in propionate (p = 0.03). When comparing UC and CD, differences were observed mainly in propionate (SMD = −0.76, p = 0.00001). Dietary interventions in IBD patients led to increased SCFA levels, with butyrate showing the most improvement (SMD = 1.03), suggesting the potential therapeutic value of dietary modulation.
Conclusions
In conclusion, this meta-analysis demonstrates a significant reduction in fecal SCFA levels in patients with IBD, particularly during active phases of the disease and most markedly in CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiome, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
- Centre for Host-Microbiome Interactions, King's College London, London WC2R 2LS, UK.
- Department of Pharmacology, Medical University Astana, Astana 010000, Kazakhstan.
ORCID-Profile: Laura Chulenbayeva, Samat Kozhakhmetov, Almagul Kushugulova
Förderung
- the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Zitieren
APA
Chulenbayeva, L., Jarmukhanov, Z., Kaliyekova, K., Kozhakhmetov, S., & Kushugulova, A. (2025). Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomolecules, 15(7), 1017. https://doi.org/10.3390/biom15071017
Vancouver
Chulenbayeva L, Jarmukhanov Z, Kaliyekova K, Kozhakhmetov S, Kushugulova A. Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomolecules. 2025;15(7):1017. doi:10.3390/biom15071017
BibTeX
@article{Chulenbayeva2025,
author = {Chulenbayeva, Laura and Jarmukhanov, Zharkyn and Kaliyekova, Karlygash and Kozhakhmetov, Samat and Kushugulova, Almagul},
title = {Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {7},
pages = {1017},
doi = {10.3390/biom15071017}
}
EUVIMED